Abstract
Summary
The global Cystic Fibrosis Transmembrane Conductance Regulator Modulator market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LPI (LP Information)' newest research report, the “Cystic Fibrosis Transmembrane Conductance Regulator Modulator Industry Forecast” looks at past sales and reviews total world Cystic Fibrosis Transmembrane Conductance Regulator Modulator sales in 2023, providing a comprehensive analysis by region and market sector of projected Cystic Fibrosis Transmembrane Conductance Regulator Modulator sales for 2024 through 2030. With Cystic Fibrosis Transmembrane Conductance Regulator Modulator sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cystic Fibrosis Transmembrane Conductance Regulator Modulator industry.
This Insight Report provides a comprehensive analysis of the global Cystic Fibrosis Transmembrane Conductance Regulator Modulator landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cystic Fibrosis Transmembrane Conductance Regulator Modulator portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cystic Fibrosis Transmembrane Conductance Regulator Modulator market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cystic Fibrosis Transmembrane Conductance Regulator Modulator and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cystic Fibrosis Transmembrane Conductance Regulator Modulator.
United States market for Cystic Fibrosis Transmembrane Conductance Regulator Modulator is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Cystic Fibrosis Transmembrane Conductance Regulator Modulator is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Cystic Fibrosis Transmembrane Conductance Regulator Modulator is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Cystic Fibrosis Transmembrane Conductance Regulator Modulator players cover Vertex Pharmaceuticals, ReCode Therapeutics, Arcturus Therapeutics, AbbVie and Spirovant Sciences and etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Cystic Fibrosis Transmembrane Conductance Regulator Modulator market by product type, application, key players and key regions and countries.
Segmentation by type
Correctors
Potentiators
Amplifiers
Segmentation by application
Clinical
Non-clinical
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Vertex Pharmaceuticals
ReCode Therapeutics
Arcturus Therapeutics
AbbVie
Spirovant Sciences
4D Molecular Therapeutics
LPI (LP Information)' newest research report, the “Cystic Fibrosis Transmembrane Conductance Regulator Modulator Industry Forecast” looks at past sales and reviews total world Cystic Fibrosis Transmembrane Conductance Regulator Modulator sales in 2023, providing a comprehensive analysis by region and market sector of projected Cystic Fibrosis Transmembrane Conductance Regulator Modulator sales for 2024 through 2030. With Cystic Fibrosis Transmembrane Conductance Regulator Modulator sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cystic Fibrosis Transmembrane Conductance Regulator Modulator industry.
This Insight Report provides a comprehensive analysis of the global Cystic Fibrosis Transmembrane Conductance Regulator Modulator landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cystic Fibrosis Transmembrane Conductance Regulator Modulator portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cystic Fibrosis Transmembrane Conductance Regulator Modulator market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cystic Fibrosis Transmembrane Conductance Regulator Modulator and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cystic Fibrosis Transmembrane Conductance Regulator Modulator.
United States market for Cystic Fibrosis Transmembrane Conductance Regulator Modulator is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Cystic Fibrosis Transmembrane Conductance Regulator Modulator is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Cystic Fibrosis Transmembrane Conductance Regulator Modulator is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Cystic Fibrosis Transmembrane Conductance Regulator Modulator players cover Vertex Pharmaceuticals, ReCode Therapeutics, Arcturus Therapeutics, AbbVie and Spirovant Sciences and etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Cystic Fibrosis Transmembrane Conductance Regulator Modulator market by product type, application, key players and key regions and countries.
Segmentation by type
Correctors
Potentiators
Amplifiers
Segmentation by application
Clinical
Non-clinical
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Vertex Pharmaceuticals
ReCode Therapeutics
Arcturus Therapeutics
AbbVie
Spirovant Sciences
4D Molecular Therapeutics
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size 2019-2030
2.1.2 Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Cystic Fibrosis Transmembrane Conductance Regulator Modulator Segment by Type
2.2.1 Correctors
2.2.2 Potentiators
2.2.3 Amplifiers
2.3 Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size by Type
2.3.1 Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size Market Share by Type (2019-2024)
2.4 Cystic Fibrosis Transmembrane Conductance Regulator Modulator Segment by Application
2.4.1 Clinical
2.4.2 Non-clinical
2.5 Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size by Application
2.5.1 Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size Market Share by Application (2019-2024)
3 Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size by Player
3.1 Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size Market Share by Players
3.1.1 Global Cystic Fibrosis Transmembrane Conductance Regulator Modulator Revenue by Players (2019-2024)
3.1.2 Global Cystic Fibrosis Transmembrane Conductance Regulator Modulator Revenue Market Share by Players (2019-2024)
3.2 Global Cystic Fibrosis Transmembrane Conductance Regulator Modulator Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Cystic Fibrosis Transmembrane Conductance Regulator Modulator by Regions
4.1 Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size by Regions (2019-2024)
4.2 Americas Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size Growth (2019-2024)
4.3 APAC Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size Growth (2019-2024)
4.4 Europe Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size Growth (2019-2024)
4.5 Middle East & Africa Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size Growth (2019-2024)
5 Americas
5.1 Americas Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size by Country (2019-2024)
5.2 Americas Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size by Type (2019-2024)
5.3 Americas Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size by Region (2019-2024)
6.2 APAC Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size by Type (2019-2024)
6.3 APAC Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Cystic Fibrosis Transmembrane Conductance Regulator Modulator by Country (2019-2024)
7.2 Europe Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size by Type (2019-2024)
7.3 Europe Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cystic Fibrosis Transmembrane Conductance Regulator Modulator by Region (2019-2024)
8.2 Middle East & Africa Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size by Type (2019-2024)
8.3 Middle East & Africa Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.1 Global Cystic Fibrosis Transmembrane Conductance Regulator Modulator Forecast by Regions (2025-2030)
10.1.1 Global Cystic Fibrosis Transmembrane Conductance Regulator Modulator Forecast by Regions (2025-2030)
10.1.2 Americas Cystic Fibrosis Transmembrane Conductance Regulator Modulator Forecast
10.1.3 APAC Cystic Fibrosis Transmembrane Conductance Regulator Modulator Forecast
10.1.4 Europe Cystic Fibrosis Transmembrane Conductance Regulator Modulator Forecast
10.1.5 Middle East & Africa Cystic Fibrosis Transmembrane Conductance Regulator Modulator Forecast
10.2 Americas Cystic Fibrosis Transmembrane Conductance Regulator Modulator Forecast by Country (2025-2030)
10.2.1 United States Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.2.2 Canada Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.2.3 Mexico Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.2.4 Brazil Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.3 APAC Cystic Fibrosis Transmembrane Conductance Regulator Modulator Forecast by Region (2025-2030)
10.3.1 China Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.3.2 Japan Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.3.3 Korea Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.3.4 Southeast Asia Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.3.5 India Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.3.6 Australia Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.4 Europe Cystic Fibrosis Transmembrane Conductance Regulator Modulator Forecast by Country (2025-2030)
10.4.1 Germany Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.4.2 France Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.4.3 UK Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.4.4 Italy Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.4.5 Russia Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.5 Middle East & Africa Cystic Fibrosis Transmembrane Conductance Regulator Modulator Forecast by Region (2025-2030)
10.5.1 Egypt Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.5.2 South Africa Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.5.3 Israel Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.5.4 Turkey Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.5.5 GCC Countries Cystic Fibrosis Transmembrane Conductance Regulator Modulator Market Forecast
10.6 Global Cystic Fibrosis Transmembrane Conductance Regulator Modulator Forecast by Type (2025-2030)
10.7 Global Cystic Fibrosis Transmembrane Conductance Regulator Modulator Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Vertex Pharmaceuticals
11.1.1 Vertex Pharmaceuticals Company Information
11.1.2 Vertex Pharmaceuticals Cystic Fibrosis Transmembrane Conductance Regulator Modulator Product Offered
11.1.3 Vertex Pharmaceuticals Cystic Fibrosis Transmembrane Conductance Regulator Modulator Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Vertex Pharmaceuticals Main Business Overview
11.1.5 Vertex Pharmaceuticals Latest Developments
11.2 ReCode Therapeutics
11.2.1 ReCode Therapeutics Company Information
11.2.2 ReCode Therapeutics Cystic Fibrosis Transmembrane Conductance Regulator Modulator Product Offered
11.2.3 ReCode Therapeutics Cystic Fibrosis Transmembrane Conductance Regulator Modulator Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 ReCode Therapeutics Main Business Overview
11.2.5 ReCode Therapeutics Latest Developments
11.3 Arcturus Therapeutics
11.3.1 Arcturus Therapeutics Company Information
11.3.2 Arcturus Therapeutics Cystic Fibrosis Transmembrane Conductance Regulator Modulator Product Offered
11.3.3 Arcturus Therapeutics Cystic Fibrosis Transmembrane Conductance Regulator Modulator Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Arcturus Therapeutics Main Business Overview
11.3.5 Arcturus Therapeutics Latest Developments
11.4 AbbVie
11.4.1 AbbVie Company Information
11.4.2 AbbVie Cystic Fibrosis Transmembrane Conductance Regulator Modulator Product Offered
11.4.3 AbbVie Cystic Fibrosis Transmembrane Conductance Regulator Modulator Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 AbbVie Main Business Overview
11.4.5 AbbVie Latest Developments
11.5 Spirovant Sciences
11.5.1 Spirovant Sciences Company Information
11.5.2 Spirovant Sciences Cystic Fibrosis Transmembrane Conductance Regulator Modulator Product Offered
11.5.3 Spirovant Sciences Cystic Fibrosis Transmembrane Conductance Regulator Modulator Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Spirovant Sciences Main Business Overview
11.5.5 Spirovant Sciences Latest Developments
11.6 4D Molecular Therapeutics
11.6.1 4D Molecular Therapeutics Company Information
11.6.2 4D Molecular Therapeutics Cystic Fibrosis Transmembrane Conductance Regulator Modulator Product Offered
11.6.3 4D Molecular Therapeutics Cystic Fibrosis Transmembrane Conductance Regulator Modulator Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 4D Molecular Therapeutics Main Business Overview
11.6.5 4D Molecular Therapeutics Latest Developments
12 Research Findings and Conclusion